1-丙基-1H-吡唑-4-基 硼酸 | 847818-57-9

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-丙基-1H-吡唑-4-基 硼酸
• 中文别名: 1-正丙基-1H-吡唑-4-硼酸；1-丙基-1H-吡唑-4-基硼酸
• 英文名称: (1-propyl-1H-pyrazol-4-yl)boronic acid
• 英文别名: (1-propylpyrazol-4-yl)boronic acid
• CAS: 847818-57-9
• 化学式: C₆H₁₁BN₂O₂
• 分子量: 153.977
• InChiKey: WRPVRKKWSXLHKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.03
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Propylpyrazole-4-boronic acid
Synonyms: 1-Propyl-1H-pyrazol-4-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Propylpyrazole-4-boronic acid
CAS number: 847818-57-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11BN2O2
Molecular weight: 154.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-丙基-1H-吡唑-4-基 硼酸 在 四(三苯基膦)钯 、 sodium carbonate 、 一水合肼 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.25h， 生成 3-(1-acetyl-5-(4-(1-propyl-1H-pyrazol-4-yl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-6-chloro-4-phenylquinolin-2(1H)-one
  参考文献：
  名称：

  Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

  摘要：

  Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

  DOI：

  10.1021/acs.jmedchem.9b01526
• 作为产物：
  描述：

  4-溴-1-丙基-1H-吡唑 在 正丁基锂 、 硼酸三甲酯 、 ammonium chloride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 以51%的产率得到1-丙基-1H-吡唑-4-基 硼酸
  参考文献：
  名称：

  1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成

  摘要：

  从1 H-吡唑开始，合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯。所述方法中的关键步骤是吡唑环的区域选择性锂化。合成的松果酸酯在长期保存下是稳定的，可以用作有机合成中的方便试剂。

  DOI：

  10.1002/jhet.5570410612

文献信息

• Discovery of 3-Chloro-<i>N</i>-{(<i>S</i>)-[3-(1-ethyl-1<i>H</i>-pyrazol-4-yl)phenyl][(2<i>S</i>)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor
  作者：Shuji Yamamoto、Tsuyoshi Shibata、Kumi Abe、Koji Oda、Takeshi Aoki、Yasunori Kawakita、Hiroshi Kawamoto

  DOI：10.1248/cpb.c16-00314

  日期：——

  inhibitory activity. Starting from 2-chloro-N-(S)-phenyl[(2S)-piperidin-2-yl]methyl}-3-(trifluoromethyl)benzamide (2, SSR504734), the introduction of heteroaromatic rings enabled an increase in the GlyT1 inhibitory activity. Subsequent optimization led to the identification of 3-chloro-N-(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}- 4-(trifluoromethyl)pyridine-2-carboxamide (7w)

  通过叠加不同的化学型来设计新型甘氨酸转运蛋白1（GlyT1）抑制剂，以增强其抑制活性。从2-氯-N-（S）-苯基[（2S）-哌啶-2-基]甲基} -3-（三氟甲基）苯甲酰胺（2，SSR504734）开始，杂芳环的引入使得能够增加GlyT1抑制活性。随后的优化导致鉴定3-氯-N-（S）-[3-（1-乙基-1H-吡唑-4-基）苯基] [（2S）-哌啶-2-基]甲基}- 4-（三氟甲基）吡啶-2-甲酰胺（7w），在大鼠中显示出强大的GlyT1抑制活性（IC50 = 1.8 nM），良好的血浆暴露和血浆对脑的渗透，足以评估该化合物的药理特性。
• Nickel‐Catalyzed Amination of Silyloxyarenes through C–O Bond Activation
  作者：Eric M. Wiensch、John Montgomery

  DOI：10.1002/anie.201806790

  日期：2018.8.20

  Silyloxyarenes were utilized as electrophilic coupling partners with amines in the synthesis of aniline derivatives. A diverse range of amine substrates were used, including cyclic or acyclic secondary amines, secondary anilines, and sterically hindered primary anilines. Additionally, a range of sterically hindered and unhindered primary aliphatic amines were employed, which have previously been challenging with

  在苯胺衍生物的合成中，甲硅烷氧基芳烃被用作与胺的亲电子偶联伴侣。使用了多种胺底物，包括环状或无环仲胺，仲苯胺和位阻伯苯胺。另外，使用了一系列空间受阻和不受阻碍的伯脂族伯胺，这些伯胺以前对其他种类的芳基醚亲电试剂具有挑战性。举例说明了甲硅烷基氧芳烃与芳基甲基醚的正交偶联，其中两个C-O亲电试剂之间的选择性由配体控制确定，从而使任一亲电试剂实现互补和选择性的后期多样化。最后，
• [EN] INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS<br/>[FR] INDOLYL-PIPÉRIDINYL BENZYLAMINES INHIBITRICES DE LA BÊTA-TRYPTASE
  申请人：SANOFI SA

  公开号：WO2011079102A1

  公开（公告）日：2011-06-30

  The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of formula (I), wherein R1, R2 and R3 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines. In one of the embodiments, there is provided the compounds of formula (I) wherein R3 is (II).

  本发明公开并要求一系列取代的吲哚基-哌啶基苄胺化合物，其公式为（I），其中R1、R2和R3如本文所述。更具体地说，本发明的化合物是β-tryptase的抑制剂，因此可用作药物制剂。此外，本发明还公开了取代的吲哚基-哌啶基苄胺的制备方法。在其中一个实施例中，提供了公式（I）的化合物，其中R3是（II）。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS
  申请人：FONDAZIONE ST ITALIANO TECNOLOGIA

  公开号：WO2021116999A1

  公开（公告）日：2021-06-17

  The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

  本发明涉及式(Ia)的化合物或药学上可接受的盐、水合物、溶剂合物、包合物、多晶型、立体异构体，还揭示了包含式(Ia)的化合物的药物组合物以及利用式(Ib)的化合物，特别是用于治疗破坏Rad51-BRCA2相互作用有益的疾病或紊乱的用途。
• Discovery, Optimization, and Biological Characterization of 2,3,6‐Trisubstituted Pyridine‐Containing M ₄ Positive Allosteric Modulators
  作者：Jeffrey W. Schubert、Scott T. Harrison、James Mulhearn、Robert Gomez、Robert Tynebor、Kristen Jones、Jaime Bunda、Barbara Hanney、Jenny Miu‐Chen Wai、Chris Cox、John A. McCauley、John M. Sanders、Brian Magliaro、Julie O'Brien、Natasa Pajkovic、Sarah L. Huszar Agrapides、Anne Taylor、Anthony Gotter、Sean M. Smith、Jason Uslaner、Susan Browne、Stefania Risso、Melissa Egbertson

  DOI：10.1002/cmdc.201900088

  日期：2019.5.6

  Herein we describe the discovery and optimization of a new series of 2,3-disubstituted and 2,3,6-trisubstituted muscarinic acetylcholine receptor 4 (M4 ) positive allosteric modulators (PAMs). Iterative libraries enabled rapid exploration of one-dimensional structure-activity relationships (SAR) and identification of potency-enhancing heterocycle and N-alkyl pyrazole substituents. Further optimization

  在此，我们描述了一系列新的2,3-二取代和2,3,6-三取代毒蕈碱乙酰胆碱受体4（M4）正变构调节剂（PAMs）的发现和优化。迭代库使您能够快速探索一维结构-活性关系（SAR），并鉴定出增强效价的杂环和N-烷基吡唑取代基。进一步的优化导致鉴定出有效的，受体亚型选择性，脑渗透性工具化合物24（7- [3- [1-[（[1-氟环戊基）甲基]吡唑-4-基] -6-甲基-2 -吡啶基] -3-甲氧基肉桂啉）。它在临床前测定中可有效预测抗精神病作用，可在大鼠和小鼠中产生剂量依赖性的苯丙胺诱导的运动过度，但在M4基因敲除小鼠中则无效。